These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 24251846)
21. An introduction to predictive modelling of drug concentration in anaesthesia monitors. DeCou J; Johnson K Anaesthesia; 2017 Jan; 72 Suppl 1():58-69. PubMed ID: 28044328 [TBL] [Abstract][Full Text] [Related]
22. Clinical Pharmacokinetics and Pharmacodynamics of Propofol. Sahinovic MM; Struys MMRF; Absalom AR Clin Pharmacokinet; 2018 Dec; 57(12):1539-1558. PubMed ID: 30019172 [TBL] [Abstract][Full Text] [Related]
28. Dose adjustment of anaesthetics in the morbidly obese. Ingrande J; Lemmens HJ Br J Anaesth; 2010 Dec; 105 Suppl 1():i16-23. PubMed ID: 21148651 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Barker CI; Germovsek E; Hoare RL; Lestner JM; Lewis J; Standing JF Adv Drug Deliv Rev; 2014 Jun; 73(100):127-39. PubMed ID: 24440429 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic-based minibolus delivery as an alternative to continuous infusion for drugs that exhibit a biophase lag. Kern SE; Westenskow DR J Pharmacokinet Biopharm; 1997 Apr; 25(2):191-208. PubMed ID: 9408859 [TBL] [Abstract][Full Text] [Related]
31. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Knibbe CA; Danhof M Int J Pharm; 2011 Aug; 415(1-2):9-14. PubMed ID: 21376791 [TBL] [Abstract][Full Text] [Related]
33. General anaesthesia in elderly patients with cardiovascular disorders: choice of anaesthetic agent. Das S; Forrest K; Howell S Drugs Aging; 2010 Apr; 27(4):265-82. PubMed ID: 20359259 [TBL] [Abstract][Full Text] [Related]
34. Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples. Gabrielsson J; Hjorth S; Vogg B; Harlfinger S; Gutierrez PM; Peletier L; Pehrson R; Davidsson P Eur J Pharm Sci; 2015 Jan; 67():144-159. PubMed ID: 25435491 [TBL] [Abstract][Full Text] [Related]
35. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Frey N; Laveille C; Paraire M; Francillard M; Holford NH; Jochemsen R Br J Clin Pharmacol; 2003 Feb; 55(2):147-57. PubMed ID: 12580986 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924 [TBL] [Abstract][Full Text] [Related]
37. Predictors of onset and offset of drug effect. Schnider TW; Minto CF Eur J Anaesthesiol Suppl; 2001; 23():26-31. PubMed ID: 11766242 [TBL] [Abstract][Full Text] [Related]
39. Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing. Gotta V; Cools F; van Ammel K; Gallacher DJ; Visser SA; Sannajust F; Morissette P; Danhof M; van der Graaf PH J Pharmacol Toxicol Methods; 2015; 72():1-10. PubMed ID: 25556117 [TBL] [Abstract][Full Text] [Related]
40. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. Yamazaki S AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]